CGuard Prime Updated Nov 13
The next catalyst is FDA approval of the CGuard Prime 80cm delivery system, anticipated in Q4 2026 (any day now). Approval would enable a fuller U.S. commercial relaunch after the 135cm recall. Separately, the company plans to submit a PMA supplement for an enhanced CGuard Prime for CAS procedures in December 2026. The stock's ~17% drop today reflects the dilutive $37.5M offering, not the TCAR approval itself.
- FDA approved CGuard Prime for TCAR procedures on Nov 12, 2026, doubling the U.S. addressable market to ~75,000 annual carotid stenting procedures (adding 35,000+ TCAR procedures).
- The CGUARDIANS II pivotal trial supporting the TCAR approval reported 100% acute device success and zero adverse events at 30 days, a strong safety/efficacy profile.
- Analyst consensus is bullish: 8 Buy/Strong Buy vs 1 Hold (0 Sell) as of Nov 2026, with a mean price target of $3.33 (versus the current ~$0.64 stock price).
- Voluntary recall of the CGuard Prime 135cm delivery system in May 2026 paused U.S. commercialization and forced a 2026 revenue guidance withdrawal, raising questions about manufacturing/quality execution.
- The $37.5M public offering priced on Nov 13, 2026 is heavily dilutive: 7.34M shares plus pre-funded warrants for 50.35M shares and common warrants for 43.27M shares, pressuring the stock (down ~17% today to $0.64).
- Cash burned quickly: $19.2M at Q3 2026 vs $54.2M at year-end 2025, and the company has a history of losses and a going-concern risk.